Activity of a New Cephalosporin, CXA-101 (FR264205), against β-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients

CXA-101, previously designated FR264205, is a new antipseudomonal cephalosporin. We evaluated the activity of CXA-101 against a highly challenging collection of β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit (ICU) patien...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Moya, Bartolome, Zamorano, Laura, Juan, Carlos, Pérez, José L., Ge, Yigong, Oliver, Antonio
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology (ASM) 2010
Materias:
Susceptibility
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2825979/
https://ncbi.nlm.nih.gov/pubmed/20086158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01104-09
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares